MX2021015300A - Métodos de producción de un anticuerpo anti-¿4¿7. - Google Patents
Métodos de producción de un anticuerpo anti-¿4¿7.Info
- Publication number
- MX2021015300A MX2021015300A MX2021015300A MX2021015300A MX2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A MX 2021015300 A MX2021015300 A MX 2021015300A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- methods
- vedolizumab
- producing
- integrin antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se proporcionan métodos para purificar un anticuerpo integrina anti-¿4ß7, tal como vedolizumab, a partir de una solución líquida, por ejemplo, de una recolección clarificada de cultivo de células de mamífero. La invención se refiere, entre otras cosas, a métodos de purificación para controlar la cantidad de sustancias relacionadas con el producto y/o impurezas relacionadas con el proceso presentes en preparaciones purificadas de un anticuerpo integrina anti-¿4ß7, o fragmento de unión al antígeno del mismo, por ejemplo, vedolizumab. También se proporcionan composiciones que comprenden un anticuerpo anti-¿4ß7 y usos del mismo para tratar un trastorno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859494P | 2019-06-10 | 2019-06-10 | |
| PCT/US2020/037059 WO2020252069A1 (en) | 2019-06-10 | 2020-06-10 | METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015300A true MX2021015300A (es) | 2022-02-03 |
Family
ID=73781728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015300A MX2021015300A (es) | 2019-06-10 | 2020-06-10 | Métodos de producción de un anticuerpo anti-¿4¿7. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220267449A1 (es) |
| EP (1) | EP3980466A4 (es) |
| JP (1) | JP2022536486A (es) |
| CN (1) | CN114375307A (es) |
| AR (1) | AR119270A1 (es) |
| AU (1) | AU2020290943A1 (es) |
| BR (1) | BR112021024897A2 (es) |
| CA (1) | CA3143167A1 (es) |
| IL (1) | IL288825A (es) |
| MA (1) | MA56129A (es) |
| MX (1) | MX2021015300A (es) |
| PL (1) | PL439809A1 (es) |
| TW (1) | TW202112818A (es) |
| WO (1) | WO2020252069A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021521168A (ja) * | 2018-04-10 | 2021-08-26 | ドクター レディズ ラボラトリーズ リミテッド | 安定な抗体製剤 |
| EP4376878A1 (en) * | 2021-07-29 | 2024-06-05 | Dr. Reddy's Laboratories Limited | Method to control high molecular weight aggregates in an antibody composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2014142882A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
-
2020
- 2020-06-10 CA CA3143167A patent/CA3143167A1/en active Pending
- 2020-06-10 MA MA056129A patent/MA56129A/fr unknown
- 2020-06-10 PL PL439809A patent/PL439809A1/pl unknown
- 2020-06-10 AU AU2020290943A patent/AU2020290943A1/en active Pending
- 2020-06-10 AR ARP200101641A patent/AR119270A1/es unknown
- 2020-06-10 MX MX2021015300A patent/MX2021015300A/es unknown
- 2020-06-10 US US17/596,421 patent/US20220267449A1/en active Pending
- 2020-06-10 TW TW109119563A patent/TW202112818A/zh unknown
- 2020-06-10 WO PCT/US2020/037059 patent/WO2020252069A1/en unknown
- 2020-06-10 CN CN202080049572.2A patent/CN114375307A/zh active Pending
- 2020-06-10 EP EP20822340.4A patent/EP3980466A4/en active Pending
- 2020-06-10 BR BR112021024897A patent/BR112021024897A2/pt unknown
- 2020-06-10 JP JP2021573298A patent/JP2022536486A/ja active Pending
-
2021
- 2021-12-09 IL IL288825A patent/IL288825A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022536486A (ja) | 2022-08-17 |
| IL288825A (en) | 2022-02-01 |
| TW202112818A (zh) | 2021-04-01 |
| MA56129A (fr) | 2022-04-13 |
| PL439809A1 (pl) | 2022-12-05 |
| CN114375307A (zh) | 2022-04-19 |
| EP3980466A1 (en) | 2022-04-13 |
| CA3143167A1 (en) | 2020-12-17 |
| BR112021024897A2 (pt) | 2022-01-18 |
| AR119270A1 (es) | 2021-12-09 |
| EP3980466A4 (en) | 2023-06-07 |
| AU2020290943A1 (en) | 2022-02-03 |
| US20220267449A1 (en) | 2022-08-25 |
| WO2020252069A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102391259B1 (ko) | 포유류 세포 배양물을 회수하는 방법 | |
| SA519402010B1 (ar) | طرق محسنة لتعزيز إنتاجية الأجسام المضادة في مزرعة خلايا الثدييات والحد من حدوت تكتل أثناء العمليات الفرعية والصياغة وصياغات من الأجسام المضادة مستقرة يتم الحصول عليها باستخدام هذه الطرق | |
| US20140199728A1 (en) | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture | |
| PH12020500027A1 (en) | Purification of iduronate-2-sulfatase | |
| MX2021015300A (es) | Métodos de producción de un anticuerpo anti-¿4¿7. | |
| TN2012000555A1 (en) | Antibodies to human gdf8 | |
| ATE526017T1 (de) | Abscheidung von polyelektrolyten und reinigung von antikörpern | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| SG169359A1 (en) | A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses | |
| MX2009010361A (es) | Anticuerpos il-12 anti-humanos cristalinos. | |
| MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
| MX354592B (es) | Metodo para aumentar el rendimiento de las plantas y composiciones que mejoran el rendimiento. | |
| IN2014CH00378A (es) | ||
| ES2673518T3 (es) | Métodos para modificar las tasas de producción de proteínas | |
| CN106164086A (zh) | 抗体纯化方法 | |
| MX2020010191A (es) | Composiciones de virus adenoasociado (aav), métodos de fabricación y métodos de uso. | |
| NZ707753A (en) | Purification of recombinant human galactocerebroside β-galactosidase (rhgalc) | |
| JPWO2020091041A1 (ja) | 液体培地の調製方法 | |
| WO2019083319A3 (ko) | 본 빌리브란트 인자(vwf)의 함량 조절이 가능한 제8인자 및 본 빌리브란트 인자를 포함하는 조성물의 제조방법 | |
| LT2010104A (en) | Single stranded recombinant antibody fragment able to neutralize cytolytic activity of vaginolysin | |
| JP2007522817A (ja) | タンパク質の生産方法 | |
| MX2022012278A (es) | Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. | |
| EA202091883A1 (ru) | Интегрированный процесс для фильтрации компонентов из газового потока | |
| UA112521C2 (uk) | Антитіло проти gdf8 людини |